Protalix Earnings Call: EU Win, Cash Boost, Trade-Offs
TipRanks (Wed, 1-Apr 8:28 PM ET)
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
PRNewswire (Wed, 18-Mar 6:50 AM ET)
PRNewswire (Wed, 11-Mar 6:50 AM ET)
Globe Newswire (Mon, 9-Mar 8:30 AM ET)
Globe Newswire (Mon, 9-Mar 6:00 AM ET)
Ellomay Capital Announces Changes in its Principal Shareholders and Board Composition
Globe Newswire (Wed, 4-Mar 4:32 PM ET)
Market Chameleon (Mon, 2-Feb 6:09 AM ET)
Market Chameleon (Fri, 30-Jan 6:09 AM ET)
Globe Newswire (Fri, 30-Jan 9:47 AM ET)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Protalix Biotherapeutics (De) trades on the AMEX stock market under the symbol PLX.
As of April 2, 2026, PLX stock price declined to $2.12 with 544,058 million shares trading.
PLX has a beta of 1.36, meaning it tends to be more sensitive to market movements. PLX has a correlation of 0.07 to the broad based SPY ETF.
PLX has a market cap of $170.81 million. This is considered a Micro Cap stock.
Last quarter Protalix Biotherapeutics (De) reported $9 million in Revenue and -$.06 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.07.
In the last 3 years, PLX traded as high as $3.55 and as low as $.82.
The top ETF exchange traded funds that PLX belongs to (by Net Assets): IWM, IWO, VTWO, IWC, DFAS.
PLX has underperformed the market in the last year with a price return of -16.5% while the SPY ETF gained +17.9%. However, in the short term, PLX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +17.8% vs -3.8% return in SPY. But in the last 2 weeks, PLX shares have been beat by the market, returning -4.1% compared to an SPY return of -0.8%.
PLX support price is $2.11 and resistance is $2.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLX shares will trade within this expected range on the day.